Hemato Oncology Testing Market Worth $5.6 Billion by 2027 - Exclusive Report by MarketsandMarkets™
In 2022, F. Hoffmann-La Roche Ltd. (Switzerland) received FDA approval for the cobras EZH2 mutation test as a companion diagnostic for patients with follicular lymphoma
View full press release